Long-Term Experience With the DuraHeart(TM) Left-Ventricular Assist System Continues to Grow As Another Patient Surpasses Four Years of Support on the Device

By Terumo Heart Inc., PRNE
Tuesday, August 10, 2010

ANN ARBOR, Michigan, August 11, 2010 - Terumo Heart, Inc., a wholly owned subsidiary of Terumo Corporation,
today announced that another patient implanted with the DuraHeart(TM) Left
Ventricular Assist System (LVAS) has surpassed four years after receiving the
mechanical circulatory support device. Helga Gieseke, 66, who lives in the
south of Saxony-Anhalt, Germany is now one of the longest-living heart
failure recipients of this device designed to aid the pumping action of the
heart in order to circulate blood throughout her body.

Mrs. Gieseke received the DuraHeart LVAS as an investigational device in
May of 2006 after suffering from heart failure for many years. She was
treated by the Physicians at The Deutsches Herzzentrum Berlin (DHZB, German
Heart Institute Berlin) as part of the DuraHeart LVAS clinical study that
ultimately lead to CE Mark and commercialization in Europe.

"I feel fortunate to have had the opportunity to continue doing many of
the things I enjoy," said Mrs. Gieseke. "I am thankful to all of the people
involved in my care; it gives me the opportunity to spend more time with my
family and see my grandchildren grow up. I've grown accustomed to having the
device with me as it truly has become an important part of who I am; a
patient living with chronic heart disease."

Mrs. Gieseke has had a long history of heart problems; her first heart
surgery was performed in 1994. Since then, Mrs. Gieseke had undergone several
procedures including implantation of stents, pacemakers and implantable
defibrillators in an attempt to manage her condition. Despite all these
treatments, Mrs. Gieseke's condition continued to deteriorate until she found
herself unable to walk or carry out simple activities around the house
without getting chest pain. It was after admission to the local hospital in
April of 2006 that Mrs. Gieseke was told by her cardiologist, also a school
friend, that she required additional treatment. It was then that she was
referred to The Deutsches Herzzentrum Berlin (DHZB, German Heart Institute

"When Mrs. Gieseke was admitted in our Institution, she was in an
advanced stage of chronic heart failure. Only an immediate heart transplant
would have solved the problem, but a suitable donor heart was not available,"
said Professor Roland Hetzer, Director of The Deutsches Herzzentrum Berlin
(DHZB, German Heart Institute Berlin) stated. "Instead, we explained that she
would need a mechanical heart assist device and proposed that she participate
in the DuraHeart LVAS clinical trial. She has done extremely well living with
the DuraHeart LVAS, which has proven to be quite durable and capable of
providing the critical long-term support required by our heart failure

The DuraHeart LVAS can be used as a bridge to heart transplant in
patients with end stage heart failure. Due to the scarcity of donor organs,
patients can sometimes be on the waiting list for many months until a
suitable donor becomes available. During that time, a patient's condition can
deteriorate dramatically until no other alternative is available to them. The
left ventricular assist systems offer the patient a second chance while
waiting for a suitable donor

"Mrs. Gieseke is yet another excellent example of the important work that
leading Physicians around the world can accomplish in treating end stage
heart failure, supported by the people at Terumo Heart," said William Pinon,
President and CEO, Terumo Heart. "It is truly gratifying to see the impact of
our DuraHeart LVAS in bringing long-term quality of life back to patients who
otherwise would have few options for treatment in the absence of a heart

The DuraHeart LVAS is the latest-generation rotary blood pump designed
for long-term patient support. The system incorporates a centrifugal flow
rotary pump with the magnetically levitated impeller. The pump features three
position sensors and electromagnetic coils that suspend the impeller inside
the pump chamber without a single contact point. The impeller's active
magnetic levitation is designed to eliminate friction by allowing a wide gap
between blood contacting surfaces, enabling blood to flow through the pump
unimpeded in a smooth, non-turbulent fashion.

The DuraHeart LVAS is currently being studied in the DuraHeart Pivotal
U.S. Trial for Bridge-to-Transplant (BTT), a multi-center, prospective,
non-randomized study, involving 140 patients. The study, which was granted
unconditional approval in early 2010 by the U.S. Food & Drug Administration
(FDA), will evaluate the safety and efficacy of the device in helping to
sustain patients awaiting heart transplant who are at risk of death due to
end-stage heart failure. The DuraHeart LVAS carries a CE Mark and is
currently available for sale in European countries. The company has completed
clinical trial enrollment for this device in Japan. Additionally, Terumo
Heart has submitted its Destination Therapy Investigational Device Exemption
to the FDA, which is a first step in the process of obtaining approval to
begin its DuraHeart DT Clinical Trial in the U. S.

For more detailed information about the DuraHeart BTT Trial, visit
www.clinicaltrials.gov, and for more information about the DuraHeart
LVAS, visit www.terumoheart.com.

About Heart Failure

More than 22 million people suffer from heart failure worldwide with
approximately one million new patients diagnosed annually. In the setting of
an aging global population, heart failure is the number one reason for
hospitalization. The most severely ill patients need heart transplants in
order to recover. More than 8,000 people worldwide are on the list of
eligible candidates for heart transplants annually, but less than 3,000
receive a transplant each year. A large number of people who suffer from
severe heart failure do not qualify for transplantation due to other health
issues. An alternative for these patients is access to artificial mechanical

About Terumo Heart, Inc.

Terumo Heart, Inc. is a U.S. subsidiary of Terumo Corporation with
headquarters and manufacturing facilities in Ann Arbor, Michigan. The
company's focus is the innovation and introduction of products to improve the
quality of healthcare for heart failure patients. Terumo Corporation, located
in Tokyo, Japan, is a leading developer, manufacturer and global marketer of
a wide array of medical products. DuraHeart is limited to investigational use
only in the United States, and is CE marked in Europe. For more information
visit www.terumoheart.com

Robert Murphy, The Storch-Murphy Group, Ltd., +1-908-276-0777, rmurphy at storchmurphy.com

will not be displayed